A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer

Le résumé fourni par la source

The research focuses on the use of biomarkers to diagnose Alzheimer’s disease (AD) in living individuals. Biomarkers for AD are grouped into Aβ deposition, pathologic tau, and neurodegeneration. Other potential candidates for AD, which include Neurofilament light (NEFL) protein, glial fibrillary acidic protein (GFAP), and growth differentiation factor 15 (GDF15), have been found in recent studies in addition to the Aβ and tau proteins. This review primarily addresses the methods used in the study, which was published in the journal Nature Aging, to measure biomarkers using fludeoxyglucose positron emission tomography, single molecule array, cerebospinal fluid sampling and blood proteomics, and dementia investigation to date. Inferred from the analysis, plasma proteins, NEFL, GFAP, and GDF15 were shown to be highly rated in protein significance ranking and to be most consistently linked with incident dementia and AD. An individual with greater GFAP levels is 2.32 times likely to acquire dementia. Early diagnosis is crucial for those with dementia, as it ensures that they receive the help and support they need. Furthermore, new drugs, such as donanemab and lecanemab, may be able to delay the progression of AD.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.